HQH

Abrdn Healthcare Investors
CAPPED RATING

Abrdn Healthcare Investors (HQH) is rated C- (2.1/5) on Deltasharpe Prism, scored against Financial Services sector peers. Its strongest pillar is Profitability (B); its weakest is Growth (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C-
Factor Score 1.9 / 5.0
Growth
F
Factor Score 0.2 / 5.0
Profitability
B
Factor Score 3.3 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C+
Factor Score 2.5 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 4.9
EV / EBITDA N/A
Rev Growth YoY -42.1%
Gross Margin N/M
Price Return 3M -3.8%
Price Return 12M 38.9%
Catalyst Signal 0.00
Market Cap $1.3B
TTM Revenue $5.5M
Price / Sales 227.9
ROE 24.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C- (1.9) F (0.2) B (3.3) C (2.4) C+ (2.5) C- (2.1)
2026-11-05 C- (1.9) F (0.2) B (3.3) C+ (2.5) C+ (2.6) C- (2.1)
2026-10-29 C- (1.9) F (0.1) B (3.3) B (3.2) C+ (2.5) C (2.2)
2026-10-22 C- (1.9) F (0.2) B (3.2) B+ (3.5) C+ (2.5) C (2.3)
2026-10-15 C- (2.0) F (0.2) B (3.3) B- (3.1) C+ (2.5) C (2.2)
Page 1 of 4